Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis.

Chen-Hui Sun, Wei Zheng, Xin-Hu Yang, Dong-Bin Cai, Chee H Ng, Gabor S Ungvari, Hai-Yan Li, Yu-Jie Wu, Yu-Ping Ning, Yu-Tao Xiang
{"title":"Adjunctive Melatonin for Tardive Dyskinesia in Patients with Schizophrenia: A Meta-Analysis.","authors":"Chen-Hui Sun,&nbsp;Wei Zheng,&nbsp;Xin-Hu Yang,&nbsp;Dong-Bin Cai,&nbsp;Chee H Ng,&nbsp;Gabor S Ungvari,&nbsp;Hai-Yan Li,&nbsp;Yu-Jie Wu,&nbsp;Yu-Ping Ning,&nbsp;Yu-Tao Xiang","doi":"10.11919/j.issn.1002-0829.217046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities.</p><p><strong>Aims: </strong>This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia.</p><p><strong>Methods: </strong>A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes.</p><p><strong>Results: </strong>Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), <i>p</i>=0.08; <i>I<sup>2</sup></i> =0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as \"Low\". The data on the ADRs and cognitive effect were limited.</p><p><strong>Conclusions: </strong>This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.</p>","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/58/sap-29-129.PMC5579456.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Shanghai archives of psychiatry","FirstCategoryId":"95","ListUrlMain":"https://doi.org/10.11919/j.issn.1002-0829.217046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Background: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities.

Aims: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia.

Methods: A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes.

Results: Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), p=0.08; I2 =0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as "Low". The data on the ADRs and cognitive effect were limited.

Conclusions: This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
辅助褪黑素治疗精神分裂症患者迟发性运动障碍:荟萃分析。
背景:迟发性运动障碍(TD)以异常和不自主运动为特征。重要的是,TD可能会造成相当大的个人痛苦、社会和身体残疾。目的:本荟萃分析基于随机对照试验(rct),系统评估褪黑素治疗精神分裂症TD的疗效和耐受性。方法:由两名独立作者对中文(万方数据、中国知网、中国医学信息数据库)和英文(PubMed、PsycINFO、Embase、Cochrane Library数据库)数据库从建立至2017年6月8日进行计算机化系统检索。TD症状的严重程度是主要的结果测量指标,并使用Review Manager (RevMan) Version 5.3使用随机效应模型进行分析。采用Cochrane偏倚风险和Jadad量表对纳入的随机对照试验进行质量评价。采用GRADE(推荐、评估、发展和评价等级)系统推荐分级方法评估meta分析结果的总体质量水平。结果:共识别并分析了4个rct (n=130)。3项随机对照试验采用双盲法,1项随机对照试验采用Cochrane偏倚风险评估法,3项随机对照试验采用Jadad量表评价为高质量。与对照组相比,通过异常不自主运动量表(AIMS)测量,辅助褪黑素在减轻TD严重程度方面优于对照组(4个rct, n=130,加权平均差(WMD): -1.52(95%可信区间(CI): -3.24, 0.20), p=0.08;I2 =0%),尽管改善没有达到显著水平。根据GRADE方法,TD症状改善的总体证据质量被评为“低”。关于不良反应和认知效果的数据有限。结论:这项荟萃分析显示褪黑素有改善精神分裂症TD症状的潜力。未来需要更高质量和更大规模的随机对照试验来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
2341
期刊最新文献
Research Progress in Biological Studies of Schizophrenia in China in 2017. An Association Study on the Cognitive Function and the Cerebral Grey Matter Volume of Patients with First-Episode Schizophrenia. A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia. Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia. The Effect of Repetitive Transcranial Magnetic Stimulation on the Reinstatement of Methamphetamine-Induced Conditioned Place Preference in Rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1